NCT03875768 is a NA clinical trial of Tracking plus coaching in Hypertension, sponsored by Duke University.

Who is sponsoring NCT03875768?

NCT03875768 is sponsored by Duke University.

What drugs are being tested in NCT03875768?

Interventions in NCT03875768: Tracking plus coaching.

What condition does NCT03875768 study?

NCT03875768 studies Hypertension, Health Behavior.

Is NCT03875768 still recruiting?

NCT03875768 is currently completed. Last updated 16 August 2024.

Are results published for NCT03875768?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-08-16 · How we verify

NCT03875768

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nourish: A Digital Health Program to Promote the DASH Eating Plan Among Adults With High Blood Pressure

Completed NA Results posted Last updated 16 August 2024

What this trial tests

NA trial testing Tracking plus coaching in Hypertension in 301 participants. Completed in 20 March 2023.

Timeline

29 September 2020

Primary endpoint
20 March 2023

20 March 2023

Quick facts

Lead sponsor	Duke University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	301
Start date	29 September 2020
Primary completion	20 March 2023
Estimated completion	20 March 2023
Sites	1 location across United States

Drugs / interventions tested

Tracking plus coaching

Conditions studied

Hypertension — all drugs for Hypertension →
Health Behavior — all drugs for Health Behavior →

Sponsor

Duke University

Who can join

18 and older, any sex, with Hypertension or Health Behavior. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Dietary Intake as Measured by Dietary Approaches to Stop Hypertension (DASH) Score Primary · Baseline and 6 months

Participants entered their dietary intake online via the National Cancer Institute's Automated Self-Administered 24-hour (ASA24) Dietary Assessment tool to record 2 separate 24-hour dietary recalls (1 weekday and 1 weekend day). DASH dietary nutrients are then converted into a score using the method described in Mellen et al (2008). Scores ranged from 0 to 9 where a higher score indicates better adherence to the DASH dietary pattern. Change in DASH score = 6-month DASH score - Baseline DASH score.

Group	Value	95% CI
Intervention - Tracking Plus Coaching	0.3	± 1.7
Attention Control	0.3	± 1.8

Change in Systolic Blood Pressure Secondary · Baseline and 6 months

Systolic blood pressure measured in millimeters of mercury (mmHg) using the upper arm three times at 1-minute intervals after 5 minutes of quiet sitting. Blood pressure was measured 3 times at 1 minute intervals. The final 2 measurements were averaged together for analysis. Change in systolic blood pressure = 6-month systolic blood pressure - Baseline systolic blood pressure.

Group	Value	95% CI
Intervention - Tracking Plus Coaching	-5.5	± 13.0
Attention Control	-3.5	± 12.9

Change in Diastolic Blood Pressure Secondary · Baseline and 6 months

Diastolic blood pressure measured in millimeters of mercury (mmHg) using the upper arm three times at 1-minute intervals after 5 minutes of quiet sitting. Blood pressure was measured 3 times at 1 minute intervals. The final 2 measurements were averaged together for analysis. Change in diastolic blood pressure = 6-month diastolic blood pressure - Baseline diastolic blood pressure.

Group	Value	95% CI
Intervention - Tracking Plus Coaching	-3.0	± 8.6
Attention Control	-2.1	± 7.9

Adverse events — posted to ClinicalTrials.gov

Time frame: Randomization through 12 months (final endpoint of trial). Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Intervention - Tracking Plus Coaching

Serious: 6/150 (4%)

Deaths: 0/150

Attention Control

Serious: 15/151 (10%)

Deaths: 0/151

Serious adverse events (12 terms)

Reaction	System	Intervention - Tracking Pl…	Attention Control
Broken limbs/accidents	Injury, poisoning and procedural complications	—	—
Cardiovascular issues (pacemaker, MI, afib, etc.)	Cardiac disorders	—	—
Cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—
COPD related	Respiratory, thoracic and mediastinal disorders	—	—
Mental health issues	Psychiatric disorders	—	—
Arthritis	Immune system disorders	—	—
Detached retina	Eye disorders	—	—
Choking	Gastrointestinal disorders	—	—
Urological issues	Renal and urinary disorders	—	—
Magnesium deficiency	Metabolism and nutrition disorders	—	—
Breast reconstructive surgery	Reproductive system and breast disorders	—	—
Parkinsons	Nervous system disorders	—	—

Other adverse events (12 terms — click to expand)

Reaction	System	Intervention - Tracking Pl…	Attention Control
Heart rate/BP/ afib	Cardiac disorders	—	—
Various medical procedures	Surgical and medical procedures	—	—
GI issues	Gastrointestinal disorders	—	—
Sinus/respiratory issues	Respiratory, thoracic and mediastinal disorders	—	—
Fractured bones/torn ligaments	Musculoskeletal and connective tissue disorders	—	—
Immune-related issues	Immune system disorders	—	—
Kidney related issues	Renal and urinary disorders	—	—
Cancer related issues	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—
Accidents	Injury, poisoning and procedural complications	—	—
Issues with eyes	Eye disorders	—	—
Mental health challenges	Psychiatric disorders	—	—
Infections from ticks	Infections and infestations	—	—

Most-reported serious reactions: Broken limbs/accidents, Cardiovascular issues (pacemaker, MI, afib, etc.), Cancer, COPD related, Mental health issues, Arthritis, Detached retina, Choking.

Data from ClinicalTrials.gov NCT03875768 adverse events section.

Sponsor's own description

The goal of Nourish is to help adults with high blood pressure enjoy an eating pattern called DASH (Dietary Approaches to Stop Hypertension) to lower blood pressure and improve health. Nourish will use a mobile app and information about DASH to help study participants follow the DASH dietary plan by tracking what they eat and drink every day. The primary outcome of the study is 6-month change in following the DASH eating plan, as measured by 24-hour dietary recalls. The secondary outcome is change in blood pressure. Study participation will last one year.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of a Digital Intervention to Improve DASH and Blood Pressure Among US Adults.
Miller HN, Askew S, Berger MB, Kay MC, et al · · 2025 · cited 4× · PMID 39711367 · DOI 10.1161/hypertensionaha.124.23887
Sociodemographic predictors of successful screening and subsequent randomization in a digital health hypertension intervention.
Miller HN, Askew S, Berger MB, Trefney E, et al · · 2024 · cited 1× · PMID 39360240 · DOI 10.1177/20552076241281216

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other Duke University trials

Trials by the same sponsor.

NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03875768 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Duke University
Last refreshed: 16 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03875768.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing